ライフサイエンスコーパス: uveal

1 fined in separate TM beam regions within the uveal and corneoscleral meshwork for image acquisition p

2 ermline BAP1 mutations with a propensity for uveal and cutaneous melanomas and other internal maligna

3 in approximately 83% and approximately 6% of uveal and skin melanomas, respectively.

4 Of 7731 patients with posterior uveal (ciliary body and choroidal) melanoma, the AJCC tu

5 Uveal coloboma affected only the anterior segment in 8 p

6 Ninety-nine patients with uveal coloboma seen at the National Eye Institute.

7 [51.1%] and 23 men [48.9%]) and 349 with OA-uveal DLBCL (192 women [55.0%] and 157 men [45.0%]) had

8 months; 95% CI, 14.2-61.8 months) than in OA-uveal DLBCL (96.0 months; 95% CI, 67.3-124.7 months; Man

9 The 5-year survival in PVRL vs OA-uveal DLBCL differed by 17.7%, and overall survival was

10 RL was 41.4% (SE, 8.6%); among those with OA-uveal DLBCL, 59.1% (SE, 2.8%; Mantel-Cox test, P = .007)

11 For all PVRL and OA-uveal DLBCL, a Cox proportional hazards regression model

12 inal lymphoma (PVRL) and ocular adnexal (OA)-uveal DLBCL.

13 The most frequent complications were uveal effusion (9.3%) and cystoid macular edema (CME) (7

14 erostomy group, eyes developed postoperative uveal effusions (P = .04).

15 ery reduces complication rates, particularly uveal effusions.

16 volvement of the retina and vitreous without uveal infiltration in systemic lymphoma, mimicking a pri

17 anterior chamber, where they caused profound uveal inflammation and release of proinflammatory cytoki

18 %] group E eyes), isolated massive posterior uveal invasion >/= 3 mm (7/15 [47%] group D eyes, 22/102

19 istic regression analysis, massive posterior uveal invasion >/= 3 mm was more common in group D eyes

20 up E eyes), and any combination of posterior uveal invasion and optic nerve involvement (7/15 [47%] g

21 Uveal lymphoma has distinctive clinical features.

22 , ciliary body, lacrimal gland, or orbit (OA-uveal lymphoma) were included.

23 Bilateral diffuse uveal melanocytic proliferation (BDUMP) is a rare parane

24 al detachment, rapid cataract formation, and uveal melanocytic tumors.

25 tely half of the patients died of metastatic uveal melanoma (10-year rate, 48.5%; 95% CI, 43.0%-54.4%

26 uveal melanoma xenografts, 57 patients with uveal melanoma (17 patients whose tumors metastasized an

27 Forty patients with uveal melanoma (mean age, 57.98+/-14.75 years) were incl

28 lignancies among BAP1 mutation carriers were uveal melanoma (n = 60 [28%]), mesothelioma (n = 48 [22%

29 erapy (EPBT) for locally recurrent posterior uveal melanoma (PUM).

30 Uveal melanoma (UM) can be divided into prognostically s

31 e of genetic risk factors in the etiology of uveal melanoma (UM) has been strongly suggested, the gen

32 expression profile (GEP) testing segregates uveal melanoma (UM) into 2 main prognostic classes.

33 Uveal melanoma (UM) is a genetically and biologically di

34 Human uveal melanoma (UM) is a major ocular malignant tumor wi

35 Uveal melanoma (UM) is a rare intraocular tumor that, si

36 Uveal melanoma (UM) is the most common cancer in adult e

37 Uveal melanoma (UM) is the most common primary intraocul

38 Uveal melanoma (UM) is unique among cancers in displayin

39 istopathologic growth patterns of metastatic uveal melanoma (UM) to the liver.

40 Uveal melanoma (UM) was a fatal malignancy in 40% to 50%

41 eration (SCD) has been observed in eyes with uveal melanoma (UM), but, to our knowledge, a definitive

42 ring the human eIF1A NTT are associated with uveal melanoma (UM).

43 e been described in the following 5 genes in uveal melanoma (UM): BAP1, EIF1AX, GNA11, GNAQ, and SF3B

44 aluated 48 patients with local recurrence of uveal melanoma after primary treatment with brachytherap

45 s known about the long-term risk of dying of uveal melanoma after treatment with radiotherapy.

46 ent selection criteria included diagnosis of uveal melanoma and adequate records to allow tumor stagi

47 ermline BAP1 mutations occur infrequently in uveal melanoma and are associated with larger tumors and

48 ntervals (95%CIs) with respect to death from uveal melanoma and death from all causes.

49 concepts of the cytogenetic pathogenesis of uveal melanoma and demonstrate the potential problems an

50 t is the most robust prognostic indicator in uveal melanoma and early studies of mostly larger tumors

51 responses were observed in one patient with uveal melanoma and four of 15 evaluable patients with RC

52 issense variants we identified are common in uveal melanoma and have been shown to constitutively act

53 between the BAP1 immunoreactivity of primary uveal melanoma and other clinicopathologic features.

54 t intraocular tumors in adults and children (uveal melanoma and retinoblastoma, respectively).

55 Clinical characteristics of uveal melanoma and the development of metastases.

56 expression with major prognostic factors for uveal melanoma and the development of metastasis.

57 Choroidal nevus is a precursor for uveal melanoma and there are no known risk factors besid

58 cal studies of systemic adjuvant therapy for uveal melanoma are enhanced by multistage trial designs

59 Recent advances in the molecular genetics of uveal melanoma are revolutionizing our understanding of

60 In this matched study, patients with uveal melanoma associated with COM were twice as likely

61 Patients with uveal melanoma associated with oculo(dermal) melanocytos

62 edictive of metastasis in patients harboring uveal melanoma associated with oculo(dermal) melanocytos

63 mber 2013 among 120 patients with metastatic uveal melanoma at 15 academic oncology centers in the Un

64 Sampling of a clinically diagnosed posterior uveal melanoma at a single site for prognostic GEP testi

65 treated with primary proton beam therapy for uveal melanoma at the oncology service at Charite-Berlin

66 lopment of a new molecular classification of uveal melanoma based on a widely available 15-gene expre

67 linical macular edema is common in eyes with uveal melanoma before and at 4 months after plaque radio

68 Patients with uveal melanoma can develop vitiligo spontaneously or fol

69 Levels of sc-Met in uveal melanoma cell cultures and in the blood serum samp

70 t was studied in the conditioned medium of 9 uveal melanoma cell lines and in the blood serum samples

71 The conditioned medium of uveal melanoma cell lines and the blood serum samples of

72 The TSN from uveal melanoma cell lines is capable of affecting the ch

73 onstructs or downregulated by sh-Jag2 in the uveal melanoma cell lines Mel285, Mel290, 92.1, and OMM1

74 resistance in newly characterized metastatic uveal melanoma cell lines to clinical-grade MEK inhibito

75 ARF6 with a small-molecule inhibitor reduces uveal melanoma cell proliferation and tumorigenesis in a

76 ere, in a series of experiments, using human uveal melanoma cells (MEL 270), human embryonic kidney c

77 Exposure of freshly cultured uveal melanoma cells to hypoxia led to an increased expr

78 Galphaq promotes the YAP-dependent growth of uveal melanoma cells, thereby identifying YAP as a suita

79 differentially expressed in cultured primary uveal melanoma cells.

80 o limit metastatic progression of monosomy 3 uveal melanoma cells.

81 ate that CD147 regulates MMP-2 expression in uveal melanoma cells.

82 Compared with uveal melanoma classified as AJCC stage I, the rate of m

83 Compared with uveal melanoma classified as T1, the rate of metastasis

84 The TSN of 1 cell line and 2 primary uveal melanoma cultures inhibited the dendritic cell mat

85 From the Wills Eye Hospital Oncology Service Uveal Melanoma Cytogenetic Database (N = 1172), 128 pati

86 every 4 months after plaque radiotherapy for uveal melanoma demonstrated OCT-evident macular edema, c

87 approximately 5% of patients with a disomy 3 uveal melanoma develop metastases, and a further 5% of m

88 , whereas somatic Galpha11 mutations mediate uveal melanoma development by constitutively up-regulati

89 ) in patients undergoing prognostication for uveal melanoma does not exist.

90 ice, of healthy donors, and of patients with uveal melanoma during follow-up.

91 our patients developed nonorbital metastatic uveal melanoma during the study period.

92 astatic death in 299 patients with posterior uveal melanoma evaluated by fine-needle aspiration biops

93 Patients diagnosed with uveal melanoma from 1995 to 2016 and treated with episcl

94 ent selection criteria included diagnosis of uveal melanoma from April 1, 2001, to April 1, 2011, ade

95 with episcleral brachytherapy for posterior uveal melanoma from January 2004 to December 2014.

96 All patients with a clinical diagnosis of uveal melanoma from May 2009 to July 2013 who underwent

97 on, and assessed the effect of NPS-2143 on a uveal melanoma Galpha11 mutant.

98 One patient without a family history of uveal melanoma had a single nucleotide substitution in t

99 date, the role of germline BAP1 mutations in uveal melanoma has not been characterized.

100 The treatment of uveal melanoma has seen a shift towards eye conserving t

101 The techniques for assessing prognosis in uveal melanoma have evolved from simple physical feature

102 se patients from 6 families had a history of uveal melanoma in 1 relative, and 2 patients from 2 addi

103 cause of death was metastatic disease due to uveal melanoma in 561 patients.

104 nhance the host's antitumor immunity against uveal melanoma in approximately one third of patients.

105 Both had a family history of uveal melanoma in at least 1 relative.

106 The number with uveal melanoma in PES studies has been small.

107 ents who underwent secondary enucleation for uveal melanoma in the London Ocular Oncology Service, be

108 d, repeatable system for dividing metastatic uveal melanoma into distinct prognostic subgroups, espec

109 A diagnosis of choroidal melanoma (ie, any uveal melanoma involving the choroid).

110 Uveal melanoma is a rare tumour with no established trea

111 Uveal melanoma is a serious life-threatening intraocular

112 Thus, uveal melanoma is among a small group of cancers associa

113 pression of the oncoprotein c-Met in primary uveal melanoma is associated with metastatic progression

114 Uveal melanoma is characterized by mutations in GNAQ and

115 loss following episcleral brachytherapy for uveal melanoma is difficult to predict for individual pa

116 results challenge the belief that metastatic uveal melanoma is immunotherapy resistant and support th

117 Uveal melanoma is the most common primary cancer of the

118 Uveal melanoma is the most common primary intraocular ma

119 ion regarding the long-term risk of dying of uveal melanoma may be useful to clinicians when counseli

120 ERK phosphorylation associated with ADH2 and uveal melanoma mutants was rectified by NPS-2143.

121 Patients undergoing enucleation for uveal melanoma need to be informed of the possibility of

122 temic metastasis compared with patients with uveal melanoma not associated with COM.

123 tosis group was matched with 2 patients with uveal melanoma not associated with ocular melanocytosis

124 Metastatic death from uveal melanoma occurs almost exclusively with tumors sho

125 Our findings implicate CYSLTR2 as a uveal melanoma oncogene and highlight the critical role

126 of certain heterotrimeric G proteins, drive uveal melanoma oncogenesis by triggering multiple downst

127 ht the critical role of Galphaq signaling in uveal melanoma pathogenesis.

128 A committee was formed to create uveal melanoma patient-specific data fields.

129 oma specific mortality among newly diagnosed uveal melanoma patients after five years.

130 rm outcomes concerning globe preservation in uveal melanoma patients after proton beam therapy with t

131 p metastases, and a further 5% of monosomy 3 uveal melanoma patients exhibit disease-free survival fo

132 in vivo and a subset of liver metastases of uveal melanoma patients express activated forms of ERBB2

133 atment and long-term surveillance of treated uveal melanoma patients is necessary.

134 Uveal melanoma patients with ischemic retinal detachment

135 Uveal melanoma patients with metastatic disease usually

136 but show only modest efficacy in metastatic uveal melanoma patients.

137 us could be determined in 97.3% (n = 110) of uveal melanoma patients.

138 ecent discovery of major driver mutations in uveal melanoma provide a rational basis for development

139 Patients with metastatic uveal melanoma received at least 3 vaccinations with aut

140 e 3, 2003, and March 18, 2008, patients with uveal melanoma received SDRT monotherapy (group 1, 60 pa

141 Of 1059 patients with uveal melanoma sampled for status of chromosomes 3, 6, a

142 We analyzed genomics data from 136 uveal melanoma samples and found a recurrent mutation in

143 of proinflammatory genes in freshly cultured uveal melanoma samples was studied in an in vitro 24-hou

144 To examine the all-cause mortality and uveal melanoma specific mortality among newly diagnosed

145 C918 human uveal melanoma spheroids were implanted in the choroids

146 Although an accurate uveal melanoma staging system is needed to improve resea

147 Among the characteristics of uveal melanoma that are associated with a poor prognosis

148 tereotactic radiotherapy in the treatment of uveal melanoma that cannot be handled with ruthenium-bra

149 Uveal melanoma that spreads to the liver can be categori

150 BAP1 immunohistochemical staining of primary uveal melanoma to evaluate metastatic risk.

151 autopsy from patients who died of metastatic uveal melanoma to the liver.

152 e after I-125 brachytherapy in patients with uveal melanoma treated and followed in a Spanish referra

153 ospective chart review of 7872 patients with uveal melanoma treated at the Ocular Oncology Service, W

154 dy reviewing data from patients with primary uveal melanoma treated between October 2003 and October

155 nd histology slides of patients with primary uveal melanoma treated by enucleation were reviewed.

156 We analyzed 14 patients with metastatic uveal melanoma treated with dendritic cell vaccination.

157 Patients with uveal melanoma treated with plaque radiotherapy were div

158 onic lymphocytic leukemia, breast cancer and uveal melanoma tumor samples, we show that hundreds of c

159 ein kinase pathway that is activated in most uveal melanoma tumors.

160 sc-Met levels in patients with nonmetastatic uveal melanoma vs patients with metastatic uveal melanom

161 Metastasis of uveal melanoma was 2.8 times higher in patients with iri

162 quencing from blood samples of patients with uveal melanoma was correlated with clinical characterist

163 cleral necrosis after plaque radiotherapy of uveal melanoma was detected in 1% of cases.

164 nts aged 45 to 79 years with newly diagnosed uveal melanoma was recruited between 2002 and 2004 from

165 The cytologic characteristics of uveal melanoma were analyzed for 150 consecutive patient

166 Main prognostic factors for the death of uveal melanoma were ciliary body involvement (HR: 1.7 (9

167 l of 21 consecutive patients with metastatic uveal melanoma were enrolled between June 7, 2013, and S

168 y, patients with melanocytosis who developed uveal melanoma were found to have double the risk for me

169 None of the mutations associated with uveal melanoma were found.

170 ients who underwent plaque brachytherapy for uveal melanoma were included.

171 tant Galpha11 proteins causing FHH2, ADH2 or uveal melanoma were transfected in CaSR-expressing HEK29

172 Seventy-eight patients with uveal melanoma were treated.

173 Indications for secondary enucleations for uveal melanoma were tumor recurrence, neovascular glauco

174 ariants in consecutive Finnish patients with uveal melanoma who come from a high-risk region for the

175 logy referral center among 507 patients with uveal melanoma who consented for collection of blood sam

176 Retrospective case series of 6 patients with uveal melanoma who had developed cutaneous vitiligo and

177 Twenty-five patients with stage IV uveal melanoma who had received 0-1 prior systemic thera

178 ic variants of BAP1 in Finnish patients with uveal melanoma who live in a high-risk region for this c

179 survival in high-risk patients with primary uveal melanoma who received adjuvant sunitinib with inst

180 ce of 96 patients with clinical diagnosis of uveal melanoma who underwent prognostication at the time

181 Patients with uveal melanoma who underwent transscleral or transvitrea

182 cutive patients with a clinical diagnosis of uveal melanoma who were treated at the Cleveland Clinic

183 metastasis differs in patients with primary uveal melanoma with different grades of nuclear BAP1 imm

184 sion was found to be a peripapillary primary uveal melanoma with distinct non-pigmented and pigmented

185 al was significantly longer in patients with uveal melanoma with high nuclear BAP1 stain (P = 0.004).

186 in patients treated with proton therapy for uveal melanoma with ischemic retinal detachment prevente

187 Ninety-six patients affected by posterior uveal melanoma with large exudative retinal detachment (

188 s: Ninety-six patients affected by posterior uveal melanoma with large exudative retinal detachment (

189 disomy 3 uveal melanoma; and iv) monosomy 3 uveal melanoma with long-term survival.

190 ned subgroups of uveal melanoma: i) disomy 3 uveal melanoma with long-term survival; ii) metastasizin

191 Large series of FNAB for uveal melanoma with no extraocular recurrence have been

192 sforming our understanding and management of uveal melanoma with the ultimate goal of improving patie

193 As controls, 174 patients with uveal melanoma without metastasis were included.

194 nes and the blood serum samples of mice with uveal melanoma xenografts contained significant levels o

195 Uveal melanoma xenografts growing in the liver in vivo a

196 d in the blood serum samples of 24 mice with uveal melanoma xenografts, 57 patients with uveal melano

197 c uveal melanoma vs patients with metastatic uveal melanoma yielded an area under the curve of 0.82 (

198 From 732 patients diagnosed with uveal melanoma, 311 were treated with brachytherapy.

199 atients treated with plaque radiotherapy for uveal melanoma, 73 (1%) developed radiotherapy-induced s

200 y period 515 enucleations were performed for uveal melanoma, 99 (19%) of which were secondary enuclea

201 ying YAP as a suitable therapeutic target in uveal melanoma, a GNAQ/GNA11-initiated human malignancy.

202 alpha subunits, are the driver oncogenes in uveal melanoma, and mutations in Gq-linked G protein-cou

203 eir lifetime, mostly malignant mesothelioma, uveal melanoma, and so on.

204 enase [LDH]) perform poorly in patients with uveal melanoma, and the search for new biomarkers is nee

205 Early detection of posterior uveal melanoma, at a point when the tumor is small, can

206 All were referred because of suspected uveal melanoma, based on ultrasonographic imaging.

207 indicated only in case of re-recurrences of uveal melanoma, but not because of secondary complicatio

208 GNAQ and GNA11 are frequently mutated in uveal melanoma, but they remain difficult therapeutic ta

209 shed new light on the molecular genetics of uveal melanoma, delineating it as an atypical tumor of t

210 high local tumor control rates in recurrent uveal melanoma, especially if the primary therapy was tr

211 ondition that can lead to the development of uveal melanoma, estimated at 1 in 400 affected patients.

212 ing brachytherapy in patients with posterior uveal melanoma, given that an understanding of the recur

213 his analysis, we included 3088 patients with uveal melanoma, identified from a hospital-based cohort

214 ted protein-1 (BAP1) gene has been linked to uveal melanoma, mesothelioma, meningioma, renal cell car

215 Of 7872 patients with uveal melanoma, oculo(dermal) melanocytosis was present

216 mutually exclusive pattern in most cases of uveal melanoma, one of the most aggressive cancers.

217 d survival suggests a biological function in uveal melanoma, possibly working to limit metastatic pro

218 s-generating study of patients with advanced uveal melanoma, selumetinib compared with chemotherapy r

219 Of 7731 patients with posterior uveal melanoma, the AJCC classification based on T was c

220 ntroduce the first transgenic mouse model of uveal melanoma, which develops cancers induced by expres

221 ee on Cancer's 7th Edition Classification of Uveal Melanoma," published online January 2, 2015, in JA

222 To determine the personalized rate of uveal melanoma-related metastasis on the basis of indivi

223 We report our experience with uveal melanoma-specific gene expression profile (GEP) te

224 edle aspiration biopsy for cytopathology and uveal melanoma-specific GEP testing for molecular progno

225 The 5-year uveal melanoma-specific survival probability was 82.9% (

226 led for enucleation as primary treatment for uveal melanoma.

227 nti-cMET monoclonal antibodies in metastatic uveal melanoma.

228 embers of this kindred reported a history of uveal melanoma.

229 r exploited as a biomarker for monitoring of uveal melanoma.

230 the initiation and metastatic progression of uveal melanoma.

231 esized to play a role in the pathogenesis of uveal melanoma.

232 cificity in the identification of metastatic uveal melanoma.

233 protein 1 gene) are frequently identified in uveal melanoma.

234 edition of the AJCCCancer Staging Manual for uveal melanoma.

235 tient-specific data fields for patients with uveal melanoma.

236 ng the standard of care in the management of uveal melanoma.

237 overall survival in patients with metastatic uveal melanoma.

238 thought to occur early in the development of uveal melanoma.

239 ars to be a prognostic factor for death from uveal melanoma.

240 individual prediction model of survival from uveal melanoma.

241 -year period of 47 consecutive patients with uveal melanoma.

242 ng response to targeted molecular therapy in uveal melanoma.

243 e targeted molecular agents in patients with uveal melanoma.

244 ccination is feasible and safe in metastatic uveal melanoma.

245 n on 5-year risk of death after diagnosis of uveal melanoma.

246 is not recommended as a prognostic marker in uveal melanoma.

247 resolution after brachytherapy of posterior uveal melanoma.

248 relationship between cutaneous vitiligo and uveal melanoma.

249 icrometastasis in the liver of patients with uveal melanoma.

250 cinoma, mesothelioma and meningioma, but not uveal melanoma.

251 TILs) could mediate regression of metastatic uveal melanoma.

252 umour regression in patients with metastatic uveal melanoma.

253 RAB31 was a predictor of metastasis risk in uveal melanoma.

254 lps determine the diagnosis and prognosis in uveal melanoma.

255 A total of 1059 patients with uveal melanoma.

256 protein-1 gene (BAP1) predispose carriers to uveal melanoma.

257 ion retinopathy and alternative therapies of uveal melanoma.

258 etected in 2 of 8 families with a history of uveal melanoma.

259 ptomatic metastases in patients with primary uveal melanoma.

260 stemic surveillance in patients with primary uveal melanoma.

261 te four clinically well-defined subgroups of uveal melanoma: i) disomy 3 uveal melanoma with long-ter

262 uveal melanoma; iii) metastasizing disomy 3 uveal melanoma; and iv) monosomy 3 uveal melanoma with l

263 r molecular prognostication in patients with uveal melanoma; however, class 1 and class 2 test result

264 -term survival; ii) metastasizing monosomy 3 uveal melanoma; iii) metastasizing disomy 3 uveal melano

265 Patient 1 had metastatic uveal melanoma; the findings resolved without interventi

266 Comprehensive multiplatform analysis of 80 uveal melanomas (UM) identifies four molecularly distinc

267 tions in GNAQ or GNA11 occurs in over 80% of uveal melanomas (UMs) and activates MAPK.

268 is associated with more benign behavior for uveal melanomas (UMs) with an otherwise high risk of met

269 Uveal melanomas are molecularly distinct from cutaneous

270 In Finland, uveal melanomas are treated centrally in the Ocular Onco

271 The vast majority of primary large uveal melanomas harbor mutually-exclusive mutations in G

272 Almost all uveal melanomas showing chromosome 3 loss (i.e., monosom

273 Twenty-four consecutive patients with uveal melanomas that were near, touching, or surrounding

274 nal experience with plaque brachytherapy for uveal melanomas with a focus on local control rates, fac

275 iogenesis was present in the ciliary body in uveal melanomas with and without extraocular extension,

276 Uveal melanomas with BAP1 mutations demonstrate sensitiv

277 g splicing factor 3B subunit 1, in low-grade uveal melanomas with good prognosis.

278 iated protein-1 (BAP1) expression of primary uveal melanomas without and with metastasis, and to anal

279 nt probe amplification were performed in the uveal melanomas.

280 ations denote a distinct molecular subset of uveal melanomas.

281 D147 and MMP-2 was analyzed in 49 samples of uveal melanomas.

282 d MMP-2 were expressed in 47 (96.0 %) of the uveal melanomas.

283 Uveal metastases are ophthalmologic tumors that have his

284 und to be an effective management option for uveal metastases associated with systemic cancer.

285 The uveal metastases were treated with teletherapy (31%), ch

286 ful for clinical evaluation of patients with uveal metastases.

287 Of 194 patients with uveal metastasis from lung cancer, 44% did not have a hi

288 There were 194 patients with a diagnosis of uveal metastasis from lung cancer.

289 Diagnosis of uveal metastasis preceded the diagnosis of primary lung

290 year mortality from the time of detection of uveal metastasis was 54%.

291 There were 374 uveal metastatic tumors originating from primary lung ca

292 Uveal neurofibromas were noted in all patients; anterior

293 l inspection can reveal additional posterior uveal pigmentary abnormalities.

294 to develop corneal infiltrates, scleral and uveal tissue necrosis with hyphema, brownish exudates in

295 In the innermost uveal TM, AF signals outlined an intricate 3-D network o

296 nd tissues, including the iris region of the uveal tract during anterior uveitis.

297 ts with suspected BDUMP to identify anterior uveal tract involvement.

298 Involvement of the anterior uveal tract may be more common than reported in the lite

299 nalysis supported a diagnosis of extraocular uveal tumor spread rather than a primary conjunctival tu

300 , all 3 patients demonstrated a reduction in uveal tumor volumes.